Smartfish´s medical nutrition product Remune® to be used in international research program for lung diseases
AMSTERDAM, OSLO AND LUND, MARCH 4th, 2021.
The Dutch consortium “Precision Medicine for more Oxygen” (P4O2) announces the official start of a research program to fundamentally improve the early detection, prevention, and treatment of lung disease. In the study, from AS will be investigated as the targeted nutritional medical product to assess the impact of nutritional support.
P402 is an ambitious research program funded by an international public-private partnership. Through the research program, the pathophysiology behind devastating lung diseases including COPD (chronic obstructive pulmonary disease) will be investigated in depth, including how to address the underlying cause through multimodal intervention. Nutritional support with Remune from Smartfish has been chosen as one of the interventions.
Remune contains essential marine fatty acids DHA and EPA as well as whey protein and vitamin D, a composition that has been specifically developed to address the needs of patients with chronic inflammation and malnutrition. A multi-center, double-blinded, randomized controlled clinical trial in COPD for nutritional management of pre-cachexia and/or cachexia has previously demonstrated significant improvements in metabolic parameters as well as exercise-induced fatigue and dyspnoea (1).
“Some patients with COPD fall into a vicious circle of malnutrition and cachexia leading to deterioration in quality of life. Through this prestigious collaboration, further insights will be generated to identify patients who will benefit most from Remune,” says Smartfish’s CEO Geir Harstad.
About the consortium
The consortium includes outstanding researchers, private partners, and patient representatives who aim to stimulate an internationally leading position in lung research for the Netherlands. Partners and sponsors are Amsterdam UMC, Leiden University Medical Center, UMC Groningen, UMC Utrecht,
Utrecht University, Maastricht University, Maastricht UMC+, TNO, Aparito, Boehringer-Ingelheim, Breathomix, Clear, Fluidda, MonitAir, Ncardia, Nutricia, Ortec Logiqcare, Philips, Quantib-U, RespiQ, Roche, Smartfish, SODAQ, Thirona, TopMD, Lung Alliance Netherlands (LAN), and the Lung Foundation Netherlands (Longfonds). The consortium is sponsored by Novartis and is co-funded by the PPP Allowance made available by Health~Holland, Top Sector Life Sciences & Health, to stimulate public-private partnerships. P4O2 is part of the Dutch National Programme for Respiratory Research (NPL) that was developed by the Netherlands Respiratory Society (NRS) in collaboration with other lung associations, specialists, and companies. More information is available at www.p4o2.org and via firstname.lastname@example.org.
About Smartfish AS
Smartfish AS is active within research, development, production and marketing of advanced clinically documented nutritional drinks in the field of medical nutrition and sports nutrition. All Smartfish products are produced on its proprietary juice-based emulsion technology platform with the marine DHA and EPA fatty acids as important ingredients. The products are mainly sold through recognized international partners and distributors. Smartfish has a number of ongoing clinical development projects and studies in close collaboration with researchers and institutions both in Norway and internationally.
The company was founded in 2001 and is located in Oslo, Norway and Lund, Sweden. Smartfish’s main shareholders are Investinor (Norway) and Industrifonden (Sweden). Learn more on https://www.smartfishnutrition.com.
For more information, please contact:
Johan Olsson, Head of R&D of Smartfish, Phone: +46 732 032 804
Geir Harstad, CEO of Smartfish, Phone: + 46 763151160
- Calder PC, Laviano A, Lonnqvist F, Muscaritoli M, Ohlander M, Schols A. Targeted medical nutrition for cachexia in chronic obstructive pulmonary disease: a randomized, controlled trial. J Cachexia Sarcopenia Muscle. 2018;9(1):28-40.